Neurocrine Biosciences Share Price (NASDAQ: NBIX)

$139.6

▲

0.66

(0.48%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Neurocrine Biosciences Stock chart to analyse performance

Neurocrine Biosciences stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$138.33
Today's High:$140.00
$139.60
0.91%
Downside
Day's Volatility :1.19%
Upside
0.29%
52 Weeks Low:$84.23
52 Weeks High:$154.61
$139.60
39.66%
Downside
52 Weeks Volatility :45.52%
Upside
9.71%

Neurocrine Biosciences Stock Returns

Period	Neurocrine Biosciences Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	11.56%	3.1%	0.0%
6 Months	21.38%	-8.4%	0.0%
1 Year	9.37%	-12.6%	0.0%
3 Years	32.81%	7.9%	-6.1%

Neurocrine Biosciences Inc. Key Stats

Check Neurocrine Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$138.94
Open	$140.0
Today's High	$140.0
Today's Low	$138.33
Market Capitalization	$13.8B
Today's Volume	$449.6K
52 Week High	$154.61
52 Week Low	$84.23
Revenue TTM	$2.5B
EBITDA	$527.6M
Earnings Per Share (EPS)	$3.38
PE Ratio	41.11
Profit Margin	13.88%
Quarterly Earnings Growth YOY	0.68%
Return On Equity TTM	13.39%

Stock Returns calculator for Neurocrine Biosciences Stock including INR - Dollar returns

The Neurocrine Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Neurocrine Biosciences investment value today

Current value as on today

₹1,15,189

Returns

₹15,189

(+15.19%)

Returns from Neurocrine Biosciences Stock

₹9,869 (+9.87%)

Dollar Returns*

₹5,319 (+5.32%)

Indian investors sentiment towards Neurocrine Biosciences Stock

32%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Neurocrine Biosciences Stock from India on INDmoney has increased by 32% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Neurocrine Biosciences Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
14.80%
Vanguard Group Inc
9.89%
Dodge & Cox
5.61%
State Street Corp
4.90%
T. Rowe Price Associates, Inc.
3.11%
JPMorgan Chase & Co
2.69%

Analyst Recommendation on Neurocrine Biosciences Stock

Rating

Trend

Buy

76%Buy

23%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Neurocrine Biosciences(by analysts ranked 0 to 5 stars)

Neurocrine Biosciences Share Price Target

What analysts predicted

Upside of 20.25%

Target:

$167.87

Current:

$139.60

Neurocrine Biosciences share price target is $167.87, a slight Upside of 20.25% compared to current price of $139.60 as per analysts' prediction.

Neurocrine Biosciences Stock Insights

Price Movement
In the last 7 days, NBIX stock has moved up by 2.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 572.6M → 687.5M (in $), with an average increase of 16.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 7.9M → 107.5M (in $), with an average increase of 92.7% per quarter

Neurocrine Biosciences Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$788.1M	↑ 74.65%
Net Income	$37.0M	↑ 75.26%
Net Profit Margin	4.69%	↑ 0.01%

	FY20	Y/Y Change
Revenue	$1.0B	↑ 32.71%
Net Income	$407.3M	↑ 1000.81%
Net Profit Margin	38.94%	↑ 34.25%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 8.38%
Net Income	$89.6M	↓ 78.0%
Net Profit Margin	7.9%	↓ 31.04%

	FY22	Y/Y Change
Revenue	$1.5B	↑ 31.34%
Net Income	$154.5M	↑ 72.43%
Net Profit Margin	10.38%	↑ 2.48%

	FY23	Y/Y Change
Revenue	$1.9B	↑ 26.76%
Net Income	$249.7M	↑ 61.62%
Net Profit Margin	13.23%	↑ 2.85%

	FY24	Y/Y Change
Revenue	$2.4B	↑ 24.81%
Net Income	$341.3M	↑ 36.68%
Net Profit Margin	14.49%	↑ 1.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$515.3M	↑ 0.02%
Net Income	$43.4M	↓ 70.62%
Net Profit Margin	8.42%	↓ 20.25%

	Q2 FY24	Q/Q Change
Revenue	$590.2M	↑ 14.54%
Net Income	$65.0M	↑ 49.77%
Net Profit Margin	11.01%	↑ 2.59%

	Q3 FY24	Q/Q Change
Revenue	$622.1M	↑ 5.4%
Net Income	$129.8M	↑ 99.69%
Net Profit Margin	20.86%	↑ 9.85%

	Q4 FY24	Q/Q Change
Revenue	$627.7M	↑ 0.9%
Net Income	$103.1M	↓ 20.57%
Net Profit Margin	16.43%	↓ 4.43%

	Q1 FY25	Q/Q Change
Revenue	$572.6M	↓ 8.78%
Net Income	$7.9M	↓ 92.34%
Net Profit Margin	1.38%	↓ 15.05%

	Q2 FY25	Q/Q Change
Revenue	$687.5M	↑ 20.07%
Net Income	$107.5M	↑ 1260.76%
Net Profit Margin	15.64%	↑ 14.26%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$780.7M	↑ 74.91%

	FY20	Y/Y Change
Profit	$1.0B	↑ 32.68%

	FY21	Y/Y Change
Profit	$1.1B	↑ 8.05%

	FY22	Y/Y Change
Profit	$1.5B	↑ 30.94%

	FY23	Y/Y Change
Profit	$1.8B	↑ 26.06%

	FY24	Y/Y Change
Profit	$2.3B	↑ 25.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$502.5M	↓ 0.83%

	Q2 FY24	Q/Q Change
Profit	$574.6M	↑ 14.35%

	Q3 FY24	Q/Q Change
Profit	$614.1M	↑ 6.87%

	Q4 FY24	Q/Q Change
Profit	$618.4M	↑ 0.7%

	Q1 FY25	Q/Q Change
Profit	$563.4M	↓ 8.89%

	Q2 FY25	Q/Q Change
Profit	$676.2M	↑ 20.02%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$152.1M	↑ 50.01%
Investing Cash Flow	$-211.1M	↓ 13.11%
Financing Cash Flow	$27.3M	↓ 7.51%

	FY20	Y/Y Change
Operating Cash Flow	$228.5M	↑ 50.28%
Investing Cash Flow	$4.1M	↓ 101.94%
Financing Cash Flow	$-157.8M	↓ 677.75%

	FY21	Y/Y Change
Operating Cash Flow	$256.5M	↑ 12.25%
Investing Cash Flow	$-130.2M	↓ 3275.61%
Financing Cash Flow	$27.4M	↓ 117.36%

	FY22	Y/Y Change
Operating Cash Flow	$339.4M	↑ 32.32%
Investing Cash Flow	$-177.1M	↑ 36.02%
Financing Cash Flow	$-234.3M	↓ 955.11%

	FY23	Y/Y Change
Operating Cash Flow	$389.9M	↑ 14.88%
Investing Cash Flow	$-467.1M	↑ 163.75%
Financing Cash Flow	$65.3M	↓ 127.87%

	FY24	Y/Y Change
Operating Cash Flow	$595.4M	↑ 52.71%
Investing Cash Flow	$-126.8M	↓ 72.85%
Financing Cash Flow	$-486.7M	↓ 845.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$130.3M	↑ 5.51%
Investing Cash Flow	$-55.0M	↓ 72.75%
Financing Cash Flow	$69.9M	↑ 97.46%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$64.6M	↓ 50.42%
Investing Cash Flow	$-28.2M	↓ 48.73%
Financing Cash Flow	$-293.0M	↓ 519.17%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$158.0M	↑ 144.58%
Investing Cash Flow	$24.7M	↓ 187.59%
Financing Cash Flow	$26.4M	↓ 109.01%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$242.5M	↑ 53.48%
Investing Cash Flow	$-68.3M	↓ 376.52%
Financing Cash Flow	$-290.0M	↓ 1198.48%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$64.8M	↓ 73.28%
Investing Cash Flow	$14.2M	↓ 120.79%
Financing Cash Flow	$-117.9M	↓ 59.34%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$102.0M	↑ 57.41%
Investing Cash Flow	$-29.0M	↓ 304.23%
Financing Cash Flow	$-3.3M	↓ 97.2%

Neurocrine Biosciences Technicals Summary

Sell

Neutral

Buy

Neurocrine Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Neurocrine Biosciences Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Neurocrine Biosciences Inc.	1.61%	21.38%	9.37%	32.81%	19.36%
Haleon Plc Spon Ads	0.52%	-8.41%	-4.81%	62.04%	30.77%
United Therapeutics Corporation	8.95%	-0.92%	-15.5%	35.55%	72.75%
Zoetis Inc.	4.01%	-9.24%	-15.65%	-1.12%	-3.33%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Neurocrine Biosciences Inc.	41.11	41.11	0.27	6.74	0.13	0.09	NA	27.22
Haleon Plc Spon Ads	21.58	21.58	3.15	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.91	11.91	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.69	26.69	2.51	6.33	0.53	0.15	0.01	11.21

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Neurocrine Biosciences Inc.	Buy	$13.8B	19.36%	41.11	13.88%
Haleon Plc Spon Ads	Buy	$43.5B	30.77%	21.58	13.81%
United Therapeutics Corporation	Buy	$13.8B	72.75%	11.91	40.36%
Zoetis Inc.	Buy	$68.6B	-3.33%	26.69	27.83%

About Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Organization	Neurocrine Biosciences
Employees	1800
CEO	Mr. Kyle W. Gano Ph.D.
Industry	Health Technology

Key Management of Neurocrine Biosciences Inc.

Name	Title
Mr. Kyle W. Gano Ph.D.	CEO & Director
Mr. Matthew C. Abernethy CPA	Chief Financial Officer
Dr. Jude Onyia Ph.D.	Chief Scientific Officer
Mr. Eric S. Benevich	Chief Commercial Officer
Dr. Eiry Wyn Roberts M.D.	Strategic Advisor
Dr. Wylie W. Vale Ph.D.	Co-Founder
Dr. Lawrence Steinman BA, M.D., Ph.D.	Co-Founder of Neurocrine
Mr. Lewis Choi	Chief Information Officer
Jane Sorensen	Head of Investor Relations
Mr. Darin M. Lippoldt Esq.	Chief Legal Officer & Corporate Secretary

Important FAQs about investing in NBIX Stock from India :

What is Neurocrine Biosciences share price today?

Neurocrine Biosciences share price today is $139.60 as on August 30, 2025 at 1:29 am IST at the close of the market. Neurocrine Biosciences share today touched a day high of $140.00 and a low of $138.33.

What is the 52 week high and 52 week low for Neurocrine Biosciences share?

Neurocrine Biosciences share touched a 52 week high of $154.61 and a 52 week low of $84.23. Neurocrine Biosciences stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $139.60, lower by 9.71% versus the 52 week high.

How to invest in Neurocrine Biosciences Stock (NBIX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Neurocrine Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neurocrine Biosciences Shares that will get you 0.0107 shares as per Neurocrine Biosciences share price of $139.60 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Neurocrine Biosciences Stock (NBIX) from India?

Indian investors can start investing in Neurocrine Biosciences (NBIX) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Neurocrine Biosciences stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Neurocrine Biosciences share’s latest price of $139.60 as on August 30, 2025 at 1:29 am IST, you will get 0.0716 shares of Neurocrine Biosciences. Learn more about fractional shares .

What are the returns that Neurocrine Biosciences has given to Indian investors in the last 5 years?

Neurocrine Biosciences stock has given 19.36% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?